AXGN Axogen, Inc.

Nasdaq axogeninc.com


$ 23.64 $ 0.32 (1.37 %)    

Thursday, 06-Nov-2025 12:41:34 EST
QQQ $ 612.47 $ -9.32 (-1.5 %)
DIA $ 468.81 $ -3.22 (-0.68 %)
SPY $ 670.48 $ -5.99 (-0.89 %)
TLT $ 89.73 $ 0.17 (0.19 %)
GLD $ 366.12 $ -1.21 (-0.33 %)
$ 23.38
$ 23.39
$ 23.55 x 600
$ 23.68 x 12
$ 23.22 - $ 23.96
$ 9.22 - $ 24.25
781,427
na
1.08B
$ 1.12
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-29-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 02-26-2025 01-01-1970 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 03-05-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-14-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-05-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-25-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 03-01-2021 12-31-2020 10-K
21 10-30-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-06-2020 03-31-2020 10-Q
24 02-24-2020 12-31-2019 10-K
25 11-06-2019 09-30-2019 10-Q
26 08-06-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 02-26-2019 12-31-2018 10-K
29 10-29-2018 09-30-2018 10-Q
30 08-01-2018 06-30-2018 10-Q
31 04-30-2018 03-31-2018 10-Q
32 02-28-2018 12-31-2017 10-K
33 11-01-2017 09-30-2017 10-Q
34 08-02-2017 06-30-2017 10-Q
35 05-04-2017 03-31-2017 10-Q
36 03-01-2017 12-31-2016 10-K
37 11-02-2016 09-30-2016 10-Q
38 08-03-2016 06-30-2016 10-Q
39 05-04-2016 03-31-2016 10-Q
40 02-29-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-axogen-raises-price-target-to-26

HC Wainwright & Co. analyst Yi Chen maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price target from $25 to $26.

 raymond-james-maintains-outperform-on-axogen-raises-price-target-to-27

Raymond James analyst Jayson Bedford maintains Axogen (NASDAQ:AXGN) with a Outperform and raises the price target from $20 t...

 canaccord-genuity-maintains-buy-on-axogen-raises-price-target-to-27

Canaccord Genuity analyst Caitlin Cronin maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price target from $24 to $27.

 citizens-maintains-market-outperform-on-axogen-raises-price-target-to-34

Citizens analyst David Turkaly maintains Axogen (NASDAQ:AXGN) with a Market Outperform and raises the price target from $26 ...

 axogen-raises-fy2025-sales-guidance-from-219000m-to-222800m-vs-219719m-est

Axogen (NASDAQ:AXGN) raises FY2025 sales outlook from $219.000 million to $222.800 million vs $219.719 million estimate.

 axogen-q3-adj-eps-012-beats-007-estimate-sales-60082m-beat-56806m-estimate

Axogen (NASDAQ:AXGN) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.07 by 66.67...

 hc-wainwright--co-initiates-coverage-on-axogen-with-buy-rating-announces-price-target-of-25

HC Wainwright & Co. analyst Yi Chen initiates coverage on Axogen (NASDAQ:AXGN) with a Buy rating and announces Price Tar...

 fda-pushes-back-axogen-avance-nerve-graft-decision-by-3-months

FDA delays Axogen's Avance Nerve Graft BLA review to December 5, after new data submission, while the company raises its fu...

 axogen-receives-fda-major-amendment-designation-delaying-avance-nerve-graft-decision

Axogen, Inc. (NASDAQ:AXGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug ...

 axogen-narrows-fy2025-sales-guidance-from-215439m-219185m-to-219000m-vs-216463m-est

Axogen (NASDAQ:AXGN) narrows FY2025 sales outlook from $215.439 million-$219.185 million to $219.000 million vs $216.463 millio...

 axogen-q2-adj-eps-012-beats-006-estimate-sales-5666m-beat-5264m-estimate

Axogen (NASDAQ:AXGN) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.06 by 93.55...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION